In August 2016, MedMarket Diligence will be releasing Report #C500, “Global Dynamics of Surgical and Interventional Cardiovascular Procedures, 2015-2022”. The report details prevalence, incidence, and caseload for the following procedures, forecast to 2022, and examines the clinical practice trends, technologies emerging on the market, and the dynamics leading to trends in procedures utilization and technology adoption.
Surgical and interventional procedures included:
- Coronary artery bypass graft (CABG) surgery
- Coronary angioplasty and stenting
- Lower extremity arterial bypass surgery
- Percutaneous transluminal angioplasty (PTA) with and without bare metal and drug-eluting stenting
- Peripheral drug-coated balloon angioplasty
- Peripheral atherectomy
- Surgical and endovascular aortic aneurysm repair
- Vena cava filter placement
- Endovenous ablation
- Mechanical venous thrombectomy
- Venous angioplasty and stenting
- Carotid endarterectomy
- Carotid artery stenting
- Cerebral thrombectomy
- Cerebral aneurysm and AVM surgical clipping
- Cerebral aneurysm and AVM coiling & flow diversion
- Left Atrial Appendage closure
- Heart valve repair and replacement surgery
- Transcatheter valve repair and replacement
- Congenital heart defect repair
- Percutaneous and surgical placement of temporary and permanent mechanical cardiac support devices
- Pacemaker implantation
- Implantable cardioverter defibrillator placement
- Cardiac resynchronization therapy device placement
- Standard SVT & VT ablation
- Transcatheter AFib ablation
In very general terms, the category “cardiovascular diseases” (CVD) refers to a variety of acute and chronic medical conditions resulting in the inability of cardiovascular system to sustain an adequate blood flow and supply of oxygen and nutrients to organs and tissues of the body. The CVD conditions could be manifested by the obstruction or deformation of arterial and venous pathways, distortion in the electrical conducting and pacing activity of the heart, and impaired pumping function of the heart muscle, or some combination of circulatory, cardiac rhythm, and myocardial disorders
The scope of this report covers surgical and interventional therapeutic procedures commonly used in the management of acute and chronic conditions affecting myocardium and vascular system. The latter include ischemic heart disease (and its life threatening manifestations like AMI, cardiogenic shock, etc.); heart failure; structural heart disorders (valvular abnormalities and congenital heart defects); peripheral artery disease (and limb and life threatening critical limb ischemia); aortic disorders (AAA, TAA and aortic dissections); acute and chronic venous conditions (such as deep venous thrombosis, pulmonary embolism and chronic venous insufficiency); neurovascular pathologies associated with high risk of hemorrhagic and ischemic stroke (such as cerebral aneurysms and AVMs, and high-grade carotid/intracranial stenosis); and cardiac rhythm disorders (requiring correction with implantable pulse generators/IPG or arrhythmia ablation).
The report offers current assessment and projected procedural dynamics (2015 to 2022) for primary market geographies (e.g., United States, Largest Western European Countries, and Major Asian States) as well as the rest-of-the-world.
The cited procedural assessments and forecasts are based on the systematic analysis of multiplicity of sources including (but not limited to):
- latest and historic company SEC filings, corporate presentations, and interviews with product management and marketing staffers;
- data released by authoritative international institutions (such as OECD and WHO), and national healthcare authorities;
- statistical updates and clinical practice guidelines from professional medical associations (like AHA, ACC, European Society of Cardiology, etc.);
- specialty presentations at major professional conferences (e.g., TCT, AHA Scientific Sessions, EuroPCR, etc.);
- publications in major medical journals (JAMA, NEJM, British Medical Journal, etc.) and specialty magazines (CathLab Digest, EP Digest, Endovascular Today, etc.);
- findings from relevant clinical trials;
- feedbacks from leading clinicians (end-users) in the field on device/procedure utilization trends and preferences; and
- policy papers by major medical insurance carriers on uses of particular surgical and interventional tools and techniques, their medical necessity and reimbursement.
Surgical and Interventional Procedures Covered in the report include:
- Coronary artery bypass graft (CABG) surgery;
- Coronary angioplasty and stenting;
- Lower extremity arterial bypass surgery;
- Percutaneous transluminal angioplasty (PTA) with and without bare metal and drug-eluting stenting;
- Peripheral drug-coated balloon angioplasty;
- Peripheral atherectomy;
- Surgical and endovascular aortic aneurysm repair;
- Vena cava filter placement
- Endovenous ablation;
- Mechanical venous thrombectomy;
- Venous angioplasty and stenting;
- Carotid endarterectomy;
- Carotid artery stenting;
- Cerebral thrombectomy;
- Cerebral aneurysm and AVM surgical clipping;
- Cerebral aneurysm and AVM coiling & flow diversion;
- Left Atrial Appendage closure;
- Heart valve repair and replacement surgery;
- Transcatheter valve repair and replacement;
- Congenital heart defect repair;
- Percutaneous and surgical placement of temporary and permanent mechanical cardiac support devices;
- Pacemaker implantation;
- Implantable cardioverter defibrillator placement;
- Cardiac resynchronization therapy device placement;
- Standard SVT & VT ablation; and
- Transcatheter AFib ablation
In 2016, cumulative worldwide volume of the aforementioned CVD procedures is projected to approach 15.05 million surgical and transcatheter interventions. This will include:
- Roughly 4.73 million coronary revascularization procedures via CABG and PCI (or about 31.4% of the total),
- Close to 4 million percutaneous and surgical peripheral artery revascularization procedures (or 26.5% of the total);
- About 2.12 million cardiac rhythm management procedures via implantable pulse generator placement and arrhythmia ablation (or 14.1% of the total);
- Over 1.65 million CVI, DVT, and PE targeting venous interventions (representing 11.0% of the total);
- More than 992 thousand surgical and transcatheter heart defect repairs and valvular interventions (or 6.6% of the total);
- Close to 931 thousand acute stroke prophylaxis and treatment procedures (contributing 6.2% of the total);
- Over 374 thousand abdominal and thoracic aortic aneurysm endovascular and surgical repairs (or 2.5% of the total); and
- Almost 254 thousand placements of temporary and permanent mechanical cardiac support devices in bridge to recovery, bridge to transplant, and destination therapy indications (accounting for about 1.7% of total procedure volume).
During the forecast period, the total worldwide volume of covered cardiovascular procedures is forecast to expand on average by 3.7% per annum to over 18.73 million corresponding surgeries and transcatheter interventions in the year 2022. The largest absolute gains can be expected in peripheral arterial interventions (thanks to explosive expansion in utilization of drug-coated balloons in all market geographies), followed by coronary revascularization (supported by continued strong growth in Chinese and Indian PCI utilization) and endovascular venous interventions (driven by grossly underserved patient caseloads within the same Chinese and Indian market geography).
The latter (venous) indications are also expected to register the fastest (5.1%) relative procedural growth, followed by peripheral revascularization (with 4.0% average annual advances) and aortic aneurysm repair (projected to show a 3.6% average annual expansion).
Geographically, Asian-Pacific (APAC) market geography accounts for slightly larger share of the global CVD procedure volume than the U.S. (29.5% vs 29,3% of the total, followed by the largest Western European states (with 23.9%) and ROW geographies (with 17.3%). Because of the faster growth in all covered categories of CVD procedures, the share of APAC can be expected to increase to 33.5% of the total by the year 2022, mostly at the expense of the U.S. and Western Europe.
Source: MedMarket Diligence, LLC; Report #C500.
However, in relative per capita terms, covered APAC territories (e.g., China and India) are continuing to lag far behind developed Western states in utilization rates of therapeutic CVD interventions with roughly 1.57 procedures per million of population performed in 2015 for APAC region versus about 13.4 and 12.3 CVD interventions done per million of population in the U.S. and largest Western European countries.
See “Global Dynamics of Surgical and Interventional Cardiovascular Procedures, 2015-2022”, Report #C500 (publishing August 2016).